Effect of treatment with Fufang Huangqi decoction(复方黄杞汤剂) on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type Ⅰ or Ⅱ myasthenia gravis  

作　　者：SHAN Caifeng ZHANG Jingsheng LIN Yi HUANG Xueshi WANG Zhanyou PAN Haiou QIAO Wenjun 

机构地区：[1]Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Liaoning Provincial Key Laboratory for Diagnosis and Treatment of Myasthenia Gravis,Liaoning University of Traditional Chinese Medicine,Shenyang 110033,China [2]Department of General Surgery,the First People's Hospital of Shenyang,Shenyang 110091,China [3]Institute of Microbial Pharmaceuticals,College of Life and Health Sciences,Northeastern University,Shenyang 110819,China [4]Institute of Health Sciences,Key Laboratory of Medical Cell Biology of Ministry of Education,China Medical University,Shenyang 110122,China [5]Liaoning University of Traditional Chinese Medicine,foreign language college,Liaoning University of Traditional Chinese Medicine,Shenyang 110033,China

出　　处：《Journal of Traditional Chinese Medicine》2022年第5期810-817,共8页中医杂志（英文版）

基　　金：Supported by the Key R&D Program of Liaoning Province,China:Research on the Development of a New Chinese Medicine for the Treatment of Myasthenia Gravis (No. 2020JH2/10300089);the Construction Project of Liaoning Provincial Key Laboratory,China:Liaoning Provincial Key Laboratory for Diagnosis and Treatment of Myasthenia Gravis (No. 2020JH13/10200022)。

摘　　要：OBJECTIVE: To investigate the clinical efficacy of Fufang Huangqi decoction(复方黄杞汤剂) in combination with pyridostigmine bromide tablets, prednisone, and tacrolimus in the treatment of type Ⅰ and Ⅱ myasthenia gravis(MG) through changes in the clinical symptom scores of 100 patients with type Ⅰ and Ⅱ MG. This study also aimed to examine dose reductions and discontinuation of these 3 Western medicines after administration of Fufang Huangqi decoction. METHODS: The clinical data on 100 patients with type I or II MG who were treated in the outpatient department of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China, between June 2017 and June 2020 were collected. The patients were divided into 4 groups based on whether they had taken pyridostigmine bromide tablets, prednisone, and/or tacrolimus at the time of their hospital visit: the Fufang Huangqi decoction group(group A), the pyridostigmine bromide tablets + Fufang Huangqi decoction group(group B), the pyridostigmine bromide tablets + prednisone + Fufang Huangqi decoction group(group C), and the pyridostigmine bromide tablets + tacrolimus + Fufang Huangqi decoction group(group D). The average treatment time was(15.6 ± 11.5) months(range: 0.5-55 months). Changes in the clinical symptom scores of the 4 groups of patients after medication administration and dose reductions and discontinuation of the 3 Western medicines were analyzed. RESULTS: An overall effectiveness rate of 86.00% was achieved in the 100 patients after treatment for(15.6 ± 11.5) months(range 0.5-55 months). The effectiveness rates were 85.71% in group A, 88.24% in group B, 76.92% in group C, and 80.00% in group D. The dosage of pyridostigmine bromide was reduced for 69.12% of the patients in group B for the first time after(4.2 ± 4.1) months, and 45.59% of the patients in group B discontinued pyridostigmine bromide after(8.8 ± 6.1) months. The dosage of pyridostigmine bromide was reduced for 46.15% of the patients in group C for the first time a

关 键 词：myasthenia gravis drug tapering drug-related side effects and adverse reactions Fufang Huangqi decoction 

分 类 号：R277.7[医药卫生—中医学]